These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 31880016)

  • 21. Reply to: "Comparison of risk of hepatocellular carcinoma between tenofovir and entecavir: One direction or no direction".
    Kim BK
    J Hepatol; 2019 Oct; 71(4):847-848. PubMed ID: 31383378
    [No Abstract]   [Full Text] [Related]  

  • 22. Is Tenofovir Associated with a Lower Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Compared With Entecavir?
    Kamal F; Khan MA
    Gastroenterology; 2020 Jun; 158(8):2311-2312. PubMed ID: 32201182
    [No Abstract]   [Full Text] [Related]  

  • 23. Tenofovir vs Entecavir for Hepatocellular Carcinoma Prevention in Patients With Chronic Hepatitis B: One of These Things Is Not Like the Other.
    Flemming JA; Terrault NA
    JAMA Oncol; 2019 Jan; 5(1):17-18. PubMed ID: 30267036
    [No Abstract]   [Full Text] [Related]  

  • 24. Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis.
    Köklü S; Tuna Y; Gülşen MT; Demir M; Köksal AŞ; Koçkar MC; Aygün C; Coban S; Ozdil K; Ataseven H; Akin E; Pürnak T; Yüksel I; Ataseven H; Ibiş M; Yildirim B; Nadir I; Küçükazman M; Akbal E; Yüksel O; Başar O; Alkan E; Baykal O
    Clin Gastroenterol Hepatol; 2013 Jan; 11(1):88-94. PubMed ID: 23063679
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs).
    Grossi G; Viganò M; Loglio A; Lampertico P
    Liver Int; 2017 Jan; 37 Suppl 1():45-51. PubMed ID: 28052621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice.
    Miquel M; Núñez Ó; Trapero-Marugán M; Díaz-Sánchez A; Jiménez M; Arenas J; Canós AP
    Ann Hepatol; 2013; 12(2):205-12. PubMed ID: 23396731
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B.
    Zhang H; Zeng W
    JAMA Oncol; 2019 Jun; 5(6):914-915. PubMed ID: 31021391
    [No Abstract]   [Full Text] [Related]  

  • 28. Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B.
    Kong Y; Jia J; Yang HI
    JAMA Oncol; 2019 Jun; 5(6):915-916. PubMed ID: 31021371
    [No Abstract]   [Full Text] [Related]  

  • 29. Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B.
    Liu Z; Sun J; Hou J
    JAMA Oncol; 2019 Jun; 5(6):915. PubMed ID: 31021388
    [No Abstract]   [Full Text] [Related]  

  • 30. Economic Analysis and Budget Impact of Tenofovir and Entecavir in the First-Line Treatment of Hepatitis B Virus in Italy.
    Ruggeri M; Basile M; Coretti S; Drago C; Cicchetti A
    Appl Health Econ Health Policy; 2017 Aug; 15(4):479-490. PubMed ID: 28197805
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study.
    Choi J; Kim HJ; Lee J; Cho S; Ko MJ; Lim YS
    JAMA Oncol; 2019 Jan; 5(1):30-36. PubMed ID: 30267080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tenofovir for the Prevention of HCC in Patients With Cirrhosis.
    Arslan F; Vahaboglu H
    Am J Gastroenterol; 2020 Feb; 115(2):302. PubMed ID: 31850932
    [No Abstract]   [Full Text] [Related]  

  • 33. Editorial: similar risk of hepatocellar carcinoma in chronic hepatitis B patients treated with tenofovir or entecavir-new clues from Europe.
    Lampertico P; Papatheodoridis GV
    Aliment Pharmacol Ther; 2021 Mar; 53(5):657-658. PubMed ID: 33566425
    [No Abstract]   [Full Text] [Related]  

  • 34. Letter: Treatment of HBeAg+ chronic hepatitis B--is tenofovir truly superior to entecavir? Authors' reply.
    Gao L; Trinh HN; Li J; Nguyen MH
    Aliment Pharmacol Ther; 2014 Jun; 39(11):1339-40. PubMed ID: 24803254
    [No Abstract]   [Full Text] [Related]  

  • 35. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
    Wang BQ; Wang YL; Shi KQ
    Liver Int; 2017 Feb; 37(2):309-310. PubMed ID: 27791331
    [No Abstract]   [Full Text] [Related]  

  • 36. Reply to: "Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B".
    Papatheodoridis G; Sypsa V; Lampertico P
    J Hepatol; 2021 Jan; 74(1):246-247. PubMed ID: 32988659
    [No Abstract]   [Full Text] [Related]  

  • 37. Response to Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
    Su TH; Kao JH
    Liver Int; 2017 Feb; 37(2):310-311. PubMed ID: 28070982
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study.
    Wu IT; Hu TH; Hung CH; Lu SN; Wang JH; Lee CM; Chen CH
    Clin Microbiol Infect; 2017 Jul; 23(7):464-469. PubMed ID: 28189857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An evaluation of entecavir for the treatment of chronic hepatitis B infection in adults.
    Lee HW; Park JY; Ahn SH
    Expert Rev Gastroenterol Hepatol; 2016; 10(2):177-86. PubMed ID: 26610256
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of risk of hepatocellular carcinoma between tenofovir and entecavir: One direction or no direction.
    Choi J; Lim YS
    J Hepatol; 2019 Oct; 71(4):846-847. PubMed ID: 31351769
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.